Replies to post #156662 on Biotech Values

[DewDiligence]

Major FoB Collaborations

[Added geography column and several new footnotes.]


Items are shown in reverse chronological order.

 
                 Date   Targets   Geography     iHub References 
 Catalent-UMN   12/12   various   Asia          #msg-82556713 
 Merck KGaA-RDY  6/12   oncology  global        #msg-76359649 
 Daiichi-Coherus 5/12   *         Asia          #msg-75397629 
 Fujifilm-Kyowa  3/12   Humira    not specified #msg-73800486 
 ACT-Bioton      2/12   insulin   US & Europe   #msg-74987123 
 ACT-AMGN       12/11   †         global        #msg-70097496, #msg-84340328 
 BAX-MNTA       12/11   various‡  global        #msg-70212854, #msg-70258421 
 Samsung-BIIB   12/11   @         not specified #msg-69629103 
 MRK-Hanwha      6/11   Enbrel    global**      #msg-64164954, #msg-64193403  
 MYL-Biocon      6/09   x         global        #msg-39119393, #msg-72421544  
 TEVA-Lonza      1/09   y         global        #msg-34930012  
 Procognia-UTR   n/a    Humira    not specified #msg-84340976

*Enbrel and Rituxan.

**US presumably excluded due to AMGN’s long-lasting patent protection.

†Humira, Remicade, Herceptin, Avastin, Rituxan, Erbitux; excludes AMGN FoB’s for AMGN’s branded drugs.

‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually.

@ Rituxan program terminated (#msg-80622249); status of other programs unknown; presumably excludes FoB’s for BIIB’s branded drugs.

x Six products: Herceptin, Neulasta, Avastin, Humira, Enbrel, one undisclosed.

y Rituxan program terminated (#msg-80236315); status of other programs unknown.